Prestige Consumer Healthcare (NYSE:PBH) Lowered to “Buy” at StockNews.com

Prestige Consumer Healthcare (NYSE:PBH) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Tuesday.

A number of other equities research analysts have also commented on the stock. TheStreet upgraded shares of Prestige Consumer Healthcare from a “c+” rating to a “b-” rating in a report on Monday, February 12th. DA Davidson reaffirmed a “neutral” rating and set a $65.00 price objective on shares of Prestige Consumer Healthcare in a research note on Thursday, May 16th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $91.25.

Prestige Consumer Healthcare Trading Down 0.5 %

Shares of PBH opened at $64.73 on Tuesday. Prestige Consumer Healthcare has a 1-year low of $55.96 and a 1-year high of $75.31. The company has a market capitalization of $3.23 billion, a P/E ratio of 15.52, a P/E/G ratio of 1.83 and a beta of 0.53. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 2.02. The firm’s 50 day simple moving average is $70.10 and its 200 day simple moving average is $65.38.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Tuesday, May 14th. The company reported $1.02 EPS for the quarter, missing analysts’ consensus estimates of $1.14 by ($0.12). The firm had revenue of $277.00 million during the quarter, compared to the consensus estimate of $287.42 million. Prestige Consumer Healthcare had a net margin of 18.60% and a return on equity of 13.48%. The firm’s revenue was down 3.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.07 EPS. Sell-side analysts forecast that Prestige Consumer Healthcare will post 4.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter valued at about $25,000. Provence Wealth Management Group bought a new stake in Prestige Consumer Healthcare during the 3rd quarter valued at approximately $26,000. Pacer Advisors Inc. grew its holdings in shares of Prestige Consumer Healthcare by 85.7% during the 4th quarter. Pacer Advisors Inc. now owns 442 shares of the company’s stock worth $27,000 after acquiring an additional 204 shares during the period. Principal Securities Inc. purchased a new position in shares of Prestige Consumer Healthcare in the 4th quarter valued at approximately $29,000. Finally, ORG Partners LLC bought a new stake in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $36,000. 99.95% of the stock is currently owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.